Nachrichten zur Alnylam Pharmaceuticals Inc. Aktie

Alnylam Pharmaceuticals: "buy"

New York (www.aktiencheck.de) - Rating-Update: Patrick Trucchio, Analyst von H.C. Wainwright & Co, stuft die Aktie von Alnylam Pharmaceuticals Inc. (ISIN:…

Alnylam Pharmaceuticals: Positives Signal - Aktienanalyse

Boston, MA (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalysevon Leerink Partners: Leerink Partners erhöht in einer aktuellen Aktienanalyse das Kursziel für die Aktie von…

Alnylam Pharmaceuticals: HELIOS-B-Daten im Fokus - Kursziel erhöht - Aktienanalyse

San Francisco (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von Wells Fargo Advisors: Die Analysten von Wells Fargo Advisors bewerten die Aktie von Alnylam…

Alnylam Pharmaceuticals: Die Markteinführung von ATTR-CM Mitte 2025? Kaufen! Aktienanalyse

New York (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von der Citigroup: Die amerikanische Großbank Citigroup stuft die Aktie von Alnylam Pharmaceuticals Inc. (ISIN:…

Alnylam Pharmaceuticals: Eines der besten Szenarien - Aktienanalyse

Toronto (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von BMO Capital Markets: Kostas Biliouris, Analyst von BMO Capital Markets, nimmt in einer aktuellen Aktienanalyse…

Alnylam Pharmaceuticals: Großartige HELIOS-B-Daten von Alnylam sehen - Aktienanalyse

St. Louis (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von Stifel: Stifel rät in einer aktuellen Aktienanalyse zum Kauf der Aktie von Alnylam Pharmaceuticals…

Alnylam Pharmaceuticals: Positive Spätphasenergebnisse mit Vutrisiran - Die Aktie explodiert! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Alnylam Pharmaceuticals-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt die Aktie von Alnylam Pharmaceuticals Inc.…

Ayala Pharmaceuticals files Form 15 to voluntarily deregister and suspend reporting obligations

…

Alnylam Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation

…

Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome

MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company,…

Antisense and RNAi Therapeutics Market Size & Share Envisaged To Reach USD 18.43 Billion By 2032, at 17.8% CAGR Growth: Polaris Market Research

The global Antisense and RNAi Therapeutics Market size and share is currently valued at USD 4.34 billion in 2023. It…

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2023 Earnings Call Transcript

…

Alnylam Pharmaceuticals Q4 2023 Earnings Preview

…

Investing in Alnylam Pharmaceuticals (NASDAQ:ALNY) five years ago would have delivered you a 104% gain

Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders might be concerned after seeing the share price drop 13% in...…

Alnylam Pharmaceuticals: R&D Day Reveals Ambitious Plans

…

Wall Street delves into Alnylam Pharmaceuticals By Investing.com

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

REDWOOD CITY, Calif., Dec. 11, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,…

Pro Research: Wall Street delves into Alnylam Pharmaceuticals By Investing.com

Pro Research: Wall Street delves into Alnylam Pharmaceuticals…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)

NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

NEW YORK, Nov. 05, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

NEW YORK, Nov. 02, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2023 Earnings Call Transcript

…

Alnylam Pharmaceuticals, Inc. 2023 Q3 - Results - Earnings Call Presentation

…

Alnylam Pharmaceuticals beats Q3 top and bottom line estimates; updates FY23 outlook

…

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY)

NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) for Potential Violations of Securities Laws

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

NEW YORK, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Alnylam Pharmaceuticals, Inc. (ALNY) for Potential Violations of Securities Laws

NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Attention Alnylam Pharmaceuticals, Inc. ("Alnylam") (NASDAQ: ALNY) shareholders:…

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Alnylam Pharmaceuticals, Inc. of an Investigation and Potential Class Action Lawsuit – (NASDAQ: ALNY)

NEW YORK, Oct. 25, 2023 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders…

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc.(ALNY)

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…

Ayala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023

AL102 1.2 mg once daily treatment achieved Overall Response Rate of 83% in the evaluable population …

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of…

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc.(ALNY)

NEW YORK, Oct. 19, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…

Ayala Pharmaceuticals Announces Closing of Merger with Biosight

REHOVOT, Israel & MONMOUTH JUNCTION, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a…

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc.

NEW YORK, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky notifies investors that it has commenced an…

Alnylam Pharmaceuticals: A Good Buy Ahead Of Phase 3 Data For Vutrisiran

…

: Alnylam to scrap sNDA for patisiran after receiving FDA complete response letter

Alnylam Pharmaceuticals Inc. ALNY said Monday it would no longer pursue its supplemental new drug application (sNDA) for patisiran as…

Oligonucleotide API Market revenue to surpass USD 5 Billion by 2035, says Research Nester

Major Oligonucleotide API Market players include Ionis Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, Biogen Inc., Sarepta Therapeutics, Alnylam Pharmaceuticals, Inc., Corden…

: Alnylam Pharmaceuticals’ stock to be halted Wednesday as FDA advisory panel reviews treatment for the Cardiomyopathy of ATTR Amyloidosis

Alnylam Pharmaceuticals Inc. ALNY said Wednesday its stock will be halted on Nasdaq through the day as a regulatory advisory…

dpa-AFX ProFeed